Teva Pharmaceutical Industries Limited logo

Teva Pharmaceutical Industries LimitedNYSE: TEVA

Profile

Sector:

Healthcare

Country:

Israel

IPO:

16 February 1982

Next earnings report:

31 January 2025

Last dividends:

27 November 2017

Next dividends:

N/A
$19.45 B
-10%vs. 3y high
96%vs. sector
-vs. 3y high
-vs. sector
-10%vs. 3y high
70%vs. sector
-12%vs. 3y high
26%vs. sector

Price

after hours | 59 min ago
$17.17+$0.36(+2.14%)

Dividend

No data over the past 3 years
$4.33 B$4.09 B
$4.33 B-$437.00 M

Analysts recommendations

Institutional Ownership

TEVA Latest News

Teva to Present at the Jefferies London Healthcare Conference
globenewswire.com08 November 2024 Sentiment: POSITIVE

TEL AVIV, Israel, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024. The presentation will begin at 8:30 A.M. Greenwich Mean Time (3.30 A.M. Eastern Time).

Are Investors Undervaluing Teva Pharmaceutical Industries (TEVA) Right Now?
zacks.com08 November 2024 Sentiment: POSITIVE

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

TEVA Stock Down 7% Despite Q3 Earnings & Sales Beat, Guidance Increase
zacks.com07 November 2024 Sentiment: NEUTRAL

TEVA reports better-than-expected third-quarter results, beating both earnings and sales estimates. However, the stock declines 7%.

Teva Pharmaceutical Industries Limited (TEVA) Q3 2024 Earnings Call Transcript
seekingalpha.com06 November 2024 Sentiment: NEUTRAL

Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Q3 2024 Earnings Conference Call November 6, 2024 8:00 AM ET Company Participants Richard Francis - President & CEO Eli Kalif - CFO Eric Hughes - Head of R&D & Chief Medical Officer Ran Meir - SVP, head of IR Conference Call Participants Umer Raffat - Evercore ISI Balaji Prasad - Barclays David Amsellem - Piper Sandler Jason Gerberry - Bank of America Chris Schott - J.P. Morgan Ash Verma - UBS Yifeng Liu - HSBC Operator Hello, and welcome to the Q3 2024 Teva Pharmaceuticals Industries Limited Earnings Conference Call.

Teva Pharmaceutical Industries (TEVA) Reports Q3 Earnings: What Key Metrics Have to Say
zacks.com06 November 2024 Sentiment: POSITIVE

While the top- and bottom-line numbers for Teva Pharmaceutical Industries (TEVA) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Teva Pharmaceutical third-quarter profit, revenue top estimates
reuters.com06 November 2024 Sentiment: POSITIVE

Teva Pharmaceutical Industries reported a larger than expected rise in third-quarter profit, boosted by strong sales of copycat medicines and its branded drugs to treat migraines and Huntington's disease.

Teva Pharmaceutical Industries (TEVA) Upgraded to Strong Buy: What Does It Mean for the Stock?
zacks.com04 November 2024 Sentiment: POSITIVE

Teva Pharmaceutical Industries (TEVA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition
globenewswire.com01 November 2024 Sentiment: POSITIVE

TEL AVIV, Israel and PARSIPPANY, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new patient- and physician-reported interim results from the Phase 4 IMPACT-TD Registry study, revealing differences between TD patients with a psychotic disorder and those with a mood disorder. The IMPACT-TD Registry is the largest study of its kind evaluating the holistic effects of TD, showing real-world treatment patterns and outcomes with once-daily AUSTEDO® XR® (deutetrabenazine) extended-release tablets and twice-daily AUSTEDO (deutetrabenazine) tablets. Teva also announced interim data from a patient-reported survey describing early, real-world experience with AUSTEDO XR. These findings are being presented at the Psych Congress 2024 taking place from October 29 – November 2 in Boston, MA.

Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as well as Results of Real-World Analyses of UZEDY® (risperidone)
globenewswire.com01 November 2024 Sentiment: POSITIVE

TEL AVIV, Israel & PARSIPPANY, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new, positive data on social functioning and quality of life from the Phase 3 Subcutaneous Olanzapine Extended-Release Injection Study (SOLARIS) trial evaluating TEV-'749 in adult patients diagnosed with schizophrenia. In the acute treatment phase of the study (Period 1), TEV-'749 demonstrated significant improvement in social functioning and quality of life across multiple validated measures from baseline to week 8. The systemic safety profile of TEV-'749 was consistent with other approved oral formulations of olanzapine, with no new safety signals identified and no PDSS events reported to date.1 In addition, in vitro data and interim results from a Phase 1 study evaluating the pharmacokinetic characteristics of TEV-'749 validate that its route of administration and drug delivery technology may effectively address the risk of PDSS development.1 These studies, highlighting the patient focused outcomes, were presented at Psych Congress 2024 taking place from October 29 – November 2, 2024, in Boston, MA.

What type of business is Teva Pharmaceutical Industries Limited?

Teva Pharmaceutical Industries Limited is a multinational pharmaceutical company headquartered in Petah Tikva, Israel. The company specializes in producing generic drugs, active pharmaceutical ingredients, and to a lesser extent, proprietary drugs. The company ranks 16th in the list of the largest pharmaceutical manufacturers and 704th in the ranking of the largest global companies by Forbes Global 2000. Teva has 80 plants in its portfolio and operates in 60 countries. Teva is a member of the American Association of Pharmaceutical Researchers and Manufacturers.

What sector is Teva Pharmaceutical Industries Limited in?

Teva Pharmaceutical Industries Limited is in the Healthcare sector

What industry is Teva Pharmaceutical Industries Limited in?

Teva Pharmaceutical Industries Limited is in the Drug Manufacturers - Specialty & Generic industry

What country is Teva Pharmaceutical Industries Limited from?

Teva Pharmaceutical Industries Limited is headquartered in Israel

When did Teva Pharmaceutical Industries Limited go public?

Teva Pharmaceutical Industries Limited initial public offering (IPO) was on 16 February 1982

What is Teva Pharmaceutical Industries Limited website?

https://www.tevapharm.com

Is Teva Pharmaceutical Industries Limited in the S&P 500?

No, Teva Pharmaceutical Industries Limited is not included in the S&P 500 index

Is Teva Pharmaceutical Industries Limited in the NASDAQ 100?

No, Teva Pharmaceutical Industries Limited is not included in the NASDAQ 100 index

Is Teva Pharmaceutical Industries Limited in the Dow Jones?

No, Teva Pharmaceutical Industries Limited is not included in the Dow Jones index

When was Teva Pharmaceutical Industries Limited the previous earnings report?

No data

When does Teva Pharmaceutical Industries Limited earnings report?

The next expected earnings date for Teva Pharmaceutical Industries Limited is 31 January 2025